welcome
Reuters

Reuters

Health

Health

Roche pairs with Zealand Pharma on obesity drug candidate

Reuters
Summary
Nutrition label

81% Informative

Danish drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug.

Zealand Pharma will receive upfront cash payments of $1.65 billion , with the possibility of milestone payments of up to $5.3 billion based on a phase 3 trial and sales development.

VR Score

90

Informative language

95

Neutral language

82

Article tone

formal

Language

English

Language complexity

61

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links